BLPH - Bellerophon stock rockets +100% on a license and commercialization deal in China

• Bellerophon Therapeutics ( NASDAQ: BLPH ) on Thursday said it had entered into a license agreement for the development and commercialization of its INOpulse nitric oxide delivery system with Baylor BioSciences in China.
• Shares of the micro-cap clinical-stage biotherapeutics company more than doubled in value to $2.46 in premarket trade.
• As per the deal, BLPH will get a license payment of $6M.
• BLPH is also entitled to royalties of 5% on net sales resulting from all of the licensed INOpulse indications within Greater China, the company said in a statement .
• Baylor BioSciences will receive exclusive rights to develop and commercialize INOpulse within Greater China for diseases associated with pulmonary hypertension.

For further details see: